- Home
- ENTX vs SRTS Comparison
ENTX vs SRTS Comparison
Compare ENTX & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- SRTS
- Stock Information
- Founded
- ENTX 2010
- SRTS 2010
- Country
- ENTX Israel
- SRTS United States
- Employees
- ENTX N/A
- SRTS N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- SRTS Medical/Dental Instruments
- Sector
- ENTX Health Care
- SRTS Health Care
- Exchange
- ENTX Nasdaq
- SRTS Nasdaq
- Market Cap
- ENTX 104.0M
- SRTS 83.9M
- IPO Year
- ENTX 2018
- SRTS 2016
- Fundamental
- Price
- ENTX N/A
- SRTS $4.87
- Analyst Decision
- ENTX Strong Buy
- SRTS Strong Buy
- Analyst Count
- ENTX 1
- SRTS 3
- Target Price
- ENTX $10.00
- SRTS $11.67
- AVG Volume (30 Days)
- ENTX 33.0K
- SRTS 56.5K
- Earning Date
- ENTX 08-08-2025
- SRTS 08-07-2025
- Dividend Yield
- ENTX N/A
- SRTS N/A
- EPS Growth
- ENTX N/A
- SRTS N/A
- EPS
- ENTX N/A
- SRTS 0.11
- Revenue
- ENTX $223,000.00
- SRTS $39,488,000.00
- Revenue This Year
- ENTX N/A
- SRTS $4.33
- Revenue Next Year
- ENTX N/A
- SRTS $31.55
- P/E Ratio
- ENTX N/A
- SRTS $42.24
- Revenue Growth
- ENTX N/A
- SRTS 24.75
- 52 Week Low
- ENTX $1.41
- SRTS $4.01
- 52 Week High
- ENTX $2.79
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- ENTX 43.51
- SRTS 44.96
- Support Level
- ENTX $1.84
- SRTS $4.61
- Resistance Level
- ENTX $2.02
- SRTS $4.81
- Average True Range (ATR)
- ENTX 0.14
- SRTS 0.19
- MACD
- ENTX -0.01
- SRTS -0.03
- Stochastic Oscillator
- ENTX 14.71
- SRTS 30.77
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.